Tango Therapeutics holder reports no beneficial stake

Rhea-AI Filing Summary

Tango Therapeutics, Inc. received an amended Schedule 13G filing in which Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo report that they beneficially own 0 shares of Tango Therapeutics common stock.

As of June 30, 2026, each reporting person discloses 0.0% of the class, with no sole or shared voting or dispositive power. They also indicate that they now hold 5 percent or less of Tango Therapeutics’ common stock.

Key Figures

Beneficial ownership: 0 shares Percent of class: 0.0% Ownership threshold status: 5 percent or less +1 more

4 metrics

Beneficial ownership 0 shares Common stock of Tango Therapeutics beneficially owned by each reporting person as of June 30, 2026

Percent of class 0.0% Percentage of Tango Therapeutics common stock beneficially owned as of June 30, 2026

Ownership threshold status 5 percent or less Ownership of 5 percent or less of a class disclosed under Item 5

Signature date 08/14/2026 Dates on which the reporting persons signed the Schedule 13G/A amendment

Key Terms

beneficially owned, SCHEDULE 13G/A, dispositive power, voting power, +1 more

5 terms

beneficially owned financial

"sets forth the aggregate number of shares of common stock of the Issuer beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

SCHEDULE 13G/A regulatory

"Amendment No. 2 to a SCHEDULE 13G/A relating to Tango Therapeutics"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

voting power financial

"Sole Voting Power 0.00 6 | Shared Voting Power 0.00"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

Reporting Persons regulatory

"The names of the persons filing this report (collectively, the 'Reporting Persons') are"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tango Therapeutics (TNGX) disclose in this Schedule 13G/A amendment?

The filing shows that Nextech Crossover I SCSp, its general partner, and related individuals now report 0 shares of Tango Therapeutics common stock, representing 0.0% of the class as of June 30, 2026.

Which shareholders are reporting on Tango Therapeutics (TNGX) in this Schedule 13G/A?

The reporting persons are Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo, collectively referred to as the Reporting Persons.

How much of Tango Therapeutics (TNGX) stock do the reporting persons now beneficially own?

As of June 30, 2026, each reporting person states they beneficially own 0 shares of Tango Therapeutics common stock, corresponding to 0.0% of the outstanding class for Schedule 13G purposes.

Do the reporting persons have any voting or dispositive power over Tango Therapeutics (TNGX) shares?

They report no sole or shared voting power and no sole or shared dispositive power over Tango Therapeutics common stock, consistent with beneficial ownership of 0 shares.

What key ownership threshold is referenced for Tango Therapeutics (TNGX) in this filing?

The filing specifies ownership of 5 percent or less of a class of Tango Therapeutics common stock, confirming the Reporting Persons are below the 5% Schedule 13G reporting threshold.

As of what date is the Tango Therapeutics (TNGX) ownership information in this Schedule 13G/A stated?

The ownership information, including 0 shares and 0.0% of the class, is stated as of June 30, 2026, and signatures are dated August 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:43 PM Accepted by SEC EDGAR 08/14/2026 - 04:40 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

87583X109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Nextech Crossover I GP S.a. r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Nextech Crossover I SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Ian Charoub

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWEDEN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Costas Constantinides

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Rocco Sgobbo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tango Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Brookline Ave., Suite 901, Boston, MA, 02215.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the 'Reporting Persons') are: Nextech Crossover I SCSp ('Nextech Crossover LP') Nextech Crossover I GP S.a r.l. ('Nextech Crossover GP') Ian Charoub ('Charoub') Costas Constantinides ('Constantinides') Rocco Sgobbo ('Sgobbo') The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 18 Zurich, Switzerland 8001
(c)	Citizenship: Nextech Crossover LP Luxembourg Nextech Crossover GP Luxembourg Charoub Sweden Constantinides Cyprus Sgobbo Switzerland
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP. Each of Nextech Crossover GP, Charoub, Constantinides and Sgobbo possesses power to direct the voting and disposition of the securities held by Nextech Crossover LP.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nextech Crossover I GP S.a. r.l.

Signature:	/s/ Ian Charoub
Name/Title:	By Ian Charoub, Manager
Date:	08/14/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Costas Constantinides, Manager
Date:	08/14/2026

Nextech Crossover I SCSp

Signature:	/s/ Ian Charoub
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Ian Charoub, Manager
Date:	08/14/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Costas Constantinides, Manager
Date:	08/14/2026

Ian Charoub

Signature:	/s/ Ian Charoub
Name/Title:	Ian Charoub
Date:	08/14/2026

Costas Constantinides

Signature:	/s/ Costas Constantinides
Name/Title:	Costas Constantinides
Date:	08/14/2026

Rocco Sgobbo

Signature:	/s/ Rocco Sgobbo
Name/Title:	Rocco Sgobbo
Date:	08/14/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons with the SEC on August 21, 2023).